PER · ASX

Percheron Therapeutics Limited (ASX:PER)

AU$0.0095

 5.0E-4 (5.556%)
ASX:Live
14/10/2025 03:45:05 PM
HALO Ords HALO Consensus Value GROWTH AUS Big Candle All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PER Overview

PER Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About PER

Website

Percheron Therapeutics Limited

Telephone

61.3.9827.8999

Address

Level 30 35 Collins Street Collins Place Melbourne, Victoria (VIC) 3000

Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

PER Price Chart

Key Stats

Market Cap

AU$9.79M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.14

Trade Value (12mth)

AU$25,221.00

1 week

-10%

1 month

0%

YTD

12.5%

1 year

-93.08%

All time high

1.85

Key Fundamentals

EPS 3 yr Growth

58.70%

EBITDA Margin

N/A

Operating Cashflow

-$16m

Free Cash Flow Return

-161.50%

ROIC

-154.10%

Interest Coverage

-1,114.40

Quick Ratio

5.10

Other Data

Shares on Issue (Fully Dilluted)

1087m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PER Announcements

Latest Announcements

Date Announcements

07 October 25

HMBD-002 Phase I Trial Results

×

HMBD-002 Phase I Trial Results

07 October 25

HMBD-002 Phase I Clinical Trial - Webinar Presentation

×

HMBD-002 Phase I Clinical Trial - Webinar Presentation

30 September 25

Progress Update on HMBD-002 Development

×

Progress Update on HMBD-002 Development

23 September 25

Chief Medical Officer and Chief Technology Officer Appointed

×

Chief Medical Officer and Chief Technology Officer Appointed

22 September 25

2025 Notice of Annual General Meeting

×

2025 Notice of Annual General Meeting

29 August 25

Percheron Receives $1.43m R&D Tax Incentive Rebate

×

Percheron Receives $1.43m R&D Tax Incentive Rebate

28 August 25

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

28 August 25

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

28 August 25

Notice of date of AGM and other relevant dates

×

Notice of date of AGM and other relevant dates

06 August 25

New Preclinical Data Reported for HMBD-002 in Breast Cancer

×

New Preclinical Data Reported for HMBD-002 in Breast Cancer

31 July 25

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

23 July 25

New Preclinical Data Reported for HMBD-002

×

New Preclinical Data Reported for HMBD-002

01 July 25

Change of Director's Interest Notice - Dr James Garner

×

Change of Director's Interest Notice - Dr James Garner

30 June 25

Ceasing to be a substantial holder from PVL

×

Ceasing to be a substantial holder from PVL

27 June 25

Percheron Therapeutics Limited Corporate Presentation

×

Percheron Therapeutics Limited Corporate Presentation

26 June 25

Percheron licenses HMBD-002 from Hummingbird Bioscience

×

Percheron licenses HMBD-002 from Hummingbird Bioscience

25 June 25

Trading Halt

×

Trading Halt

20 May 25

Notification regarding unquoted securities - PER

×

Notification regarding unquoted securities - PER

20 May 25

Change of Directors Interest Notice - Dr Charmaine Gittleson

×

Change of Directors Interest Notice - Dr Charmaine Gittleson

20 May 25

Change of Director's Interest Notice - Dr James Garner

×

Change of Director's Interest Notice - Dr James Garner

14 May 25

Letter to eligible shareholders

×

Letter to eligible shareholders

14 May 25

Letter to ineligible shareholders

×

Letter to ineligible shareholders

07 May 25

Bonus Loyalty Option Offer

×

Bonus Loyalty Option Offer

07 May 25

Proposed issue of securities - PER

×

Proposed issue of securities - PER

30 April 25

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PER Shortsell

Frequently Asked Questions

The current share price of Percheron Therapeutics Limited (PER:ASX) is AU$0.0095.
The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AU$0.14.
The 52-week low share price for Percheron Therapeutics Limited (PER:ASX)? is AU$0.00.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.0%.
Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.
The current P/E ratio for Percheron Therapeutics Limited (PER:ASX) is .
The current share price of Percheron Therapeutics Limited (PER:ASX) is AU$0.0095.
The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AU$0.14.
The 52-week low share price for Percheron Therapeutics Limited (PER:ASX)? is AU$0.00.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.0%.
Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.
The current P/E ratio for Percheron Therapeutics Limited (PER:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff